Boston Scientific Corp. Stock Plummets to New 52-Week Low at USD 69.52

Boston Scientific Corp. has reached a new 52-week low, with its stock price dropping to USD 69.52 on March 9, 2026. This decline marks a significant shift in the company's market performance, as it has experienced a 1-year performance decrease of 7.13%. In contrast, the S&P 500 has shown a robust increase of 17.78% over the same period, highlighting the challenges faced by Boston Scientific in the current market environment. The company operates within the retailing industry and boasts a market capitalization of USD 130,304 million, categorizing it as a large-cap entity. Financial metrics indicate a price-to-earnings (P/E) ratio of 69.00, while the return on equity stands at 13.88%. Additionally, Boston Scientific maintains a debt-to-equity ratio of 0.39, reflecting a relatively stable financial structure. The stock's price-to-book ratio is recorded at 5.38, further illustrating its valuation in the market. As the company navigates these market dynamics, its recent performance underscores the importance of monitoring key financial indicators.